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ORIGINAL RESEARCH ARTICLE
BACKGROUND: Hypertension caused by increased renin-angiotensin 
system activation is associated with elevated reactive oxygen species 
production. Previous studies implicate NADPH oxidase (Nox) proteins as 
important reactive oxygen species sources during renin-angiotensin system 
activation, with different Nox isoforms being potentially involved. Among 
these, Nox2 is expressed in multiple cell types, including endothelial cells, 
fibroblasts, immune cells, and microglia. Blood pressure (BP) is regulated 
at the central nervous system, renal, and vascular levels, but the cell-
specific role of Nox2 in BP regulation is unknown.
METHODS: We generated a novel mouse model with a floxed Nox2 gene 
and used Tie2-Cre, LysM Cre, or Cdh5-CreERT2 driver lines to develop 
cell-specific models of Nox2 perturbation to investigate its role in BP 
regulation.
RESULTS: Unexpectedly, Nox2 deletion in myeloid but not endothelial cells 
resulted in a significant reduction in basal BP. Both Tie2-CreNox2 knockout 
(KO) mice (in which Nox2 was deficient in both endothelial cells and myeloid 
cells) and LysM CreNox2KO mice (in which Nox2 was deficient in myeloid 
cells) had significantly lower BP than littermate controls, whereas basal BP 
was unaltered in Cdh5-CreERT2 Nox2KO mice (in which Nox2 is deficient 
only in endothelial cells). The lower BP was attributable to an increased 
NO bioavailability that dynamically dilated resistance vessels in vivo under 
basal conditions without a change in renal function. Myeloid-specific Nox2 
deletion had no effect on angiotensin II–induced hypertension, which, 
however, was blunted in Tie2-CreNox2KO mice, along with preservation of 
endothelium-dependent relaxation during angiotensin II stimulation.
CONCLUSIONS: We identify a hitherto unrecognized modulation of 
basal BP by myeloid cell Nox2, whereas endothelial cell Nox2 regulates 
angiotensin II–induced hypertension. These results identify distinct cell-
specific roles for Nox2 in BP regulation.
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The renin-angiotensin system plays a central role in blood pressure (BP) regulation, and its long-term activation contributes to hypertension. Both animal 
and human studies have implicated increased reactive 
oxygen species (ROS) production in the pathophysiology 
of angiotensin II (AngII)–dependent hypertension.1,2 ROS 
have complex cell-, source-, and context-specific roles, 
ranging from physiopathological redox signaling to inac-
tivation of nitric oxide (NO) and detrimental oxidation of 
cellular biomolecules.3,4 In experimental models, ROS 
scavengers can attenuate the hypertensive response to 
AngII,1 but randomized clinical trials of general antioxi-
dant approaches have failed to demonstrate a reduction 
in cardiovascular morbidity and mortality.5 Such global 
inhibition approaches may affect beneficial redox sig-
naling as well as detrimental oxidative stress. A better 
understanding of the roles of ROS in BP regulation and 
hypertension is therefore necessary to develop novel 
and more refined therapeutic approaches.
NADPH oxidase (Nox) family proteins are major 
sources of ROS in the cardiovascular system and are 
important in redox signaling.6,7 They contain a Nox 
catalytic subunit that mediates ROS generation through 
electron transfer from NADPH to molecular oxygen. 
Five different oxidases, each based on a distinct Nox 
catalytic subunit (Nox1–5), have been identified. They 
have tissue-specific distribution and differing modes 
of activation based on their varying requirements for 
accessory subunits. Different Nox isoforms may have 
distinct roles even in the same cell type, thought to be 
related to their coupling to different intracellular signal-
ing pathways or the production of different ROS (super-
oxide versus hydrogen peroxide).6 This is relevant from 
a therapeutic perspective because isoform-selective 
Nox inhibitors are currently being developed.8 Previous 
work suggested an involvement of Nox1 in the genesis 
of AngII-dependent hypertension. Mice globally deficient 
in p47phox, a subunit required for both Nox1 and Nox2 
function, display a reduced hypertensive response to 
AngII,9 as do global Nox1 knockout (KO) mice,10 where-
as vascular smooth muscle–targeted Nox1 transgenic 
mice develop exaggerated AngII-induced hyperten-
sion.11 The role of Nox2 is less clear. This isoform is 
expressed in endothelial cells, fibroblasts, cardiomyo-
cytes, inflammatory cells, and microglia,6 sites that 
are of interest given that BP is regulated at the central 
nervous system, renal, vascular, and cardiac levels. 
Nox2 is involved in the genesis of endothelial dysfunc-
tion in diverse models.6,7 It is interesting to note that 
ROS production in the subfornical organ in the brain is 
implicated in the vasopressor effects of AngII,12 and the 
knockout of p22phox, a subunit required for Nox1, Nox2, 
and Nox4 function, at this site blunted AngII-induced 
hypertension.13 p47phox KO mice have reduced renal 
afferent arteriolar constrictor responses to AngII,14 and 
the hypertensive effect of AngII has been shown to in-
volve infiltration of the vasculature by p47phox-containing 
T lymphocytes15 and Nox2-competent monocytic cells.16 
Although these studies suggest an involvement of Nox 
proteins in AngII-dependent hypertension, they do not 
directly establish the role of Nox2, in particular its poten-
tial cell-specific role. In this study, we have used a novel 
mouse model with a floxed Nox2 gene to study the role 
of endothelial and myeloid cell Nox2 in BP regulation. Un-
expectedly, we found that myeloid cell Nox2 has an es-
sential role in the basal regulation of BP, whereas activa-
tion of endothelial Nox2 contributes to AngII-dependent 
hypertension.
METHODS
Generation of Mice With a Floxed Nox2 Allele and 
Cell-Specific KOs
Animal studies complied with the UK Home Office Guidance 
on the Operation of the Animals (Scientific Procedures) Act, 
1986 and institutional guidelines. The generation of Nox2fl/fl 
mice was commissioned from Genoway (France). The target-
ing construct was electroporated into 129sv embryonic stem 
cells. Recombinant clones were identiﬁed by polymerase chain 
reaction and Southern blotting. After successful targeting, 
Clinical Perspective
What Is New?
• NADPH oxidases generate superoxide and are impli-
cated in the pathogenesis of hypertension.
• The NADPH oxidase Nox2 isoform is expressed 
in several cell types (such as endothelial cells and 
inflammatory cells), but exactly how it affects blood 
pressure (BP) is unclear.
• This study uses novel gene-modified mouse mod-
els to show that Nox2 in myeloid cells modulates 
basal BP, whereas endothelial cell Nox2 is involved 
in angiotensin II–dependent hypertension.
• This is the first demonstration that myeloid cell 
Nox2 regulates basal BP.
What Are the Clinical Implications?
• The finding that Nox2 in different cell types has dis-
tinct effects on BP suggests that different disease 
conditions may alter BP through effects of Nox2 in 
distinct cell types.
• It is conceivable that the effects of myeloid cells on 
basal BP may be enhanced in inflammatory settings 
where these cells are more activated.
• On the other hand, endothelial cell Nox2 activation 
may be more relevant to renin-angiotensin system–
dependent hypertension.
• The present results are relevant to the design of 
novel therapeutic approaches for hypertension by 
targeting NADPH oxidases.
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the neomycin cassette was excised with the use of flanking 
Flippase Recognition Target sites. Clones were injected into 
C57BL/6 blastocysts. Heterozygous floxed mice obtained 
from germline chimeras were back-crossed >10 generations 
with C57BL/6 mice. For generation of cell-specific KO and 
littermate controls, Nox2fl/fl females were crossed with male 
Tie2-Cre,17 LysM-Cre,18 or Cdh5-CreERT219 transgenic mice. 
Inducible deletion of Nox2 in the Cdh5-CreERT2 model was 
achieved by tamoxifen treatment (40 mg/kg IP for 3 con-
secutive days). Adult male mice 8 to 16 weeks old with cell-
specific Nox2 deletion were compared with Cre-negative Flox 
littermates.
Polymerase Chain Reaction
Confirmation of cell-specific Nox2 deletion by polymerase chain 
reaction was based on the amplification of a 225–base pair (bp) 
product that is formed only after excision of exons 1 and 2 of 
the cybb gene (forward, GGAATTGAGTTGTAAGAATCAAATGAC; 
reverse, ATGATGTGTCCCAAATGTGC). Primer GGGGCTGAATG 
TCTTCCTCT was included in the reaction to detect the 467-bp 
wild-type Nox2 sequence.
Real-time reverse transcription–polymerase chain reac-
tion with SYBR Green was used to quantify mRNA expression 
levels. ΔΔCt values were calculated with GAPDH used as 
denominator. Primer sequences were (forward and reverse) 
as follows: GAPDH, ATGACAACTTTGTCAAGCTCATTT and 
GGTCCACCACCCTGTTGCT; Nox2, ACTCCTTGGGTCAGCACTGG 
and GTTCCTGTCCAGTTGTCTTCG; p22phox, GCCCTCCACTTCC 
TGTT and GCAGATAGATCACACTGGCAAT; p40phox, CTGCTTTT 
CTGACTACCCACAG and AAGCTGCTCAAAGTCGCTCT; p47phox, 
GGACACCTTCATTCGCCATA and CTGCCACTTAACCAGGAACAT; 
p67phox, TTGAACCTGTCACACAGCAAT and CCAGCACACACAC 
AAACCTT; superoxide dismutase (SOD)-1, GGACCTCATTTT 
AATCCTCACTCTAAG and GGTCTCCAACATGCCTCTCTTC; SOD2, 
CACACATTAACGCGCAGATCA and GGTGGCGTTGAGATTGTTCA; 
SOD3, ACACCTTAGTTAACCCAGAAATCTTTTC and GGGATGGAT 
CTAGAGCATTAAGGA; and catalase, GCTGAGAAGCCTAAGAACG 
CAAT and CCCTTCGCAGCCATGTG.
Immunoblotting
Snap-frozen aortic tissue was homogenized for immunob-
lotting. Primary antibodies were as follows: Nox2 (1:1000; 
BD Biosciences, Oxford, UK), p22phox (1:1000; Santa Cruz), 
β-actin (1:4000; Sigma, UK), Nox4 (1:1000),20 endothelial 
NO synthase (eNOS; 1:1000; BD Biosciences). Actin (Sigma) 
was used as a loading control. Protein bands were visual-
ized with enhanced chemiluminescence and quantified by 
densitometry.
BP Measurement
BP telemeters (model TA11PA-C10, Data Sciences International) 
were implanted subcutaneously under isoflurane anesthe-
sia, with a 1-week recovery period before measurements.21 
Analyses were performed with Dataquest ART analysis soft-
ware. AngII (1.1 mg·kg−1·d−1) was administered via subcutane-
ous osmotic minipumps (model 1002, Alzet, Cupertino, CA) 
implanted under 2% isoflurane.21 In some experiments, Nω-
nitro-l-arginine methyl ester (L-NAME; Sigma-Aldrich, UK; 100 
mg·kg−1·d−1) was administered in the drinking water.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed in prone mice 
on a 7-T horizontal scanner (Agilent Technologies, Varian Inc, 
Palo Alto, CA) under isoflurane anesthesia.22 Body tempera-
ture was maintained at 37°C, and heart rates were main-
tained >400 bpm. Temporally resolved dynamic short-axis 
images of the carotid arteries were acquired with a cine–fast 
low-angle shot sequence with ECG and respiratory gating. 
Endothelium-dependent relaxation in vivo was assessed with 
acetylcholine (18.8 mg/kg IP).22 Pixels encompassing the 
blood pool were clustered on the basis of signal intensity 
and the vessel wall borders. Images were analyzed in the 
end-systolic and end-diastolic phases with ClinicalVolumes 
segmentation software (King’s College London; www.clinical-
volumes.com).
Other In Vivo Procedures
Echocardiography was performed with a Vevo 2100 system 
with a 40-MHz linear probe (VisualSonics, Inc) under 1.5% iso-
flurane anesthesia.23 Renal function was assessed in response 
to a short-term saline challenge (40 mL/kg 0.9% wt/vol saline, 
intraperitoneal injection). Animals were placed in an individual 
metabolic chamber (Tecniplast 3600M021) for 4 hours without 
access to food or water, and urine was collected at hourly inter-
vals.24 Metabolites were analyzed on an Advia 2400 Chemistry 
System (Siemens AG, Germany).
Ex Vivo Vascular Function
Isometric tension was quantified in descending thoracic 
aortic rings suspended in a Krebs buffer solution contain-
ing indomethacin (3 µmol/L) at 37°C, pH 7.4.21 Endothelium-
dependent relaxation was assessed from the cumulative 
dose-response to acetylcholine of rings preconstricted to 
70% of the maximal contraction to phenylephrine. In some 
experiments, rings were incubated with AngII (0.1 µmol/L for 
4 hours) in the presence or absence of the superoxide scav-
enger MnTMPyP (10 µmol/L) before the addition of other 
vasoactive agents. Basal NO bioavailability was assessed 
from the response to a single dose of N-methyl-l-arginine 
(100 µmol/L) in rings preconstricted to 30% of the maximal 
phenylephrine response.
Vascular segments from mesenteric (second-order) arteries 
were studied in a tension myograph (Danish Myo Technology, 
Denmark) in Krebs buffer at 37°C.25 Endothelium-dependent 
relaxation was assessed from the cumulative dose response 
to acetylcholine in rings preconstricted with U46619 (0.1 
μmol/L; Sigma).
ROS Assays
High-performance liquid chromatography–based detection 
of dihydroxyethidium oxidation products was performed as 
described previously.26 Aortic segments were incubated with 
or without AngII (0.1 µmol/L for 3.5 hours at 37°C) before 
the addition of dihydroxyethidium (100 µmol/L) for 30 min-
utes at 37°C in the dark. Tissue was harvested in acetonitrile, 
sonicated, and centrifuged. Supernatants were dried under 
vacuum, and pellets were stored at −80°C. For analysis, 
samples were resuspended in 120 µL PBS/DTPA and injected 
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into the high-performance liquid chromatography system. The 
superoxide-specific 2-hydroxyethidium signal was normalized 
to tissue weight.
ROS production in bone marrow and blood mononuclear 
cells was assessed by flow cytometry of cells loaded with 
dihydroxyethidium (10 µmol/L for 10 minutes at 37°C) after 
stimulation with phorbol 12-myristate 13-acetate (100 ng/mL) 
to activate the Nox2 oxidase complex.27 Bone marrow cells 
were harvested as described previously.28 Monocytes were iso-
lated by Ficoll gradient centrifugation and CD11b Microbeads 
(Miltenyi Biotech, Germany).
Vascular Morphology
In vivo perfusion fixation with 4% paraformaldehyde under 
pressure followed by paraffin embedding was used.21 Vascular 
media thickness and intima-media area were quantified in 6-µm 
sections stained with hematoxylin and eosin using Volocity soft-
ware (Volocity version 5.0, Perkin Elmer, American Fork, UT).
Coronary microvascular endothelial cells were isolated 
from mouse hearts as described previously.29
Flow Cytometry (Fluorescence-Activated Cell 
Sorter)
Quantitative analyses of leukocyte number and phenotype 
were performed by fluorescence-activated cell sorter on 
aortic tissue digests using an FACS CantoII instrument (BD 
Biosciences). In brief, animals under terminal anesthesia were 
perfused with saline through the left ventricle to eliminate cir-
culating blood. The blood-free descending and abdominal aorta 
was digested in a mixture of collagenase IV, DNase, and hyal-
uronidase at 37°C for 30 minutes, followed by trituration and 
filtration through a 70-µm nylon mesh. Cell suspensions were 
washed and blocked with anti-CD16/CD32 antibodies before 
staining. Monocytes (CD45+CD11b+Ly6G−), macrophages 
(CD45+CD11b+F4/80+), neutrophils (CD45+CD11b+Ly6G+), T 
cells (CD45+TCRβ+), and B cells (CD45+CD19+) were identi-
fied. Zombie-Aqua dye (Biolegend) was used to identify dead 
cells before fixation with 1% paraformaldehyde. Fluorescence-
minus-one–stained samples were used as negative controls. 
Data analysis was performed with FlowJo software (Tree Star 
Inc, Ashland, OR).
NO Measurement by Electron Paramagnetic 
Resonance
Aortic NO formation was measured as described previously30 
by electron paramagnetic resonance (EPR)–based spin trap-
ping with iron-diethyldithiocarbamate [Fe(DETC)2] colloid with a 
Miniscope MS400 table-top X-band spectrometer (Magnettech, 
Berlin, Germany). In brief, aortas were stimulated either with 
calcium ionophore for measurement of eNOS-derived NO lev-
els or with lipopolysaccharide to detect inducible NO synthase 
(iNOS)–derived NO formation. For lipopolysaccharide stimula-
tion, freshly prepared aortas were cut into 3-mm rings and 
incubated with 10 μg/mL lipopolysaccharide in RPMI 1640 
medium plus 10% FCS plus 1% penicillin/streptomycin for 21 
hours at 37°C, 5% CO2. Afterward, rings were transferred to a 
24-well plate filled with 1 mL Krebs-HEPES solution (pH 7.35, 
containing NaCl 99.01 mmol/L, KCl 4.69 mmol/L, CaCl2 
2.50 mmol/L, MgSO4 1.20 mmol/L, NaHCO3 25.0 mmol/L, 
K2HPO4 1.03 mmol/L, Na-HEPES 20.0 mmol/L, D-glucose 
11.1 mmol/L). For activation of eNOS, 10 µmol/L calcium 
ionophore (A12187, Sigma) was added to freshly prepared 
aortic rings in 1 mL Krebs-HEPES solution 2 minutes before 
Fe(DETC)2 spin trap addition. Then, 1 mL colloid Fe(DETC)2 
was added to each well (0.4 mmol/L in PBS Ca2+/Mg2+) and 
incubated at 37°C, 10% CO2 for 1 hour. After incubation, 
aortic rings were snap-frozen in a 1-mL syringe, and record-
ings were performed at 77 K, with a Dewar flask. Instrument 
settings were as follows: B0 field=3300 G, sweep=110 G, 
sweep time=30 seconds, steps=4096, number pass=10, 
modulation=7000 mG, power=10 mW, and gain=9 E2. Levels 
of NO are expressed as intensity of signal (arbitrary units) per 
weight of wet sample.
Statistics
All data are expressed as mean±SEM. Comparisons were 
made by Student t tests, 2-way ANOVA, or 2-way repeated 
measures ANOVA followed by Newman-Keuls post hoc tests as 
appropriate. Concentration-response curves were fitted with a 
sigmoid dose-response curve with fixed Hill slope (also known 
as 4-parameter logistic equation). Curves were compared 
by nonlinear regression analysis followed by the extra sum-
of-squares F test. Data were analyzed with GraphPad Prism 
version 6 or SigmaStat version 3.5. Values of P<0.05 were 
considered significant.
RESULTS
Tie2-Cre–Targeted Deletion of Nox2 in Mice In 
Vivo Reduces Basal BP
We first generated a mouse model with a “floxed” Nox2 
allele on a C57Bl6 background such that Cre-mediated 
recombination deletes a 3-kilobase fragment of Nox2, 
including the transcription initiation site and the first 2 ex-
ons (Figure 1A and 1B). Homozygous floxed mice (Nox2fl/
fl) were crossed with Tie-2 Cre mice to achieve endothe-
lium-targeted deletion of Nox2 (Tie2-Nox2KO), although 
myelomonocytic cells may also be targeted with this pro-
moter.31 Tie2-Nox2KO mice were born at the expected 
mendelian ratio and had no gross abnormalities up to 6 
months of age. Body and major organ weights were simi-
lar between Tie2-Nox2KO and Flox littermates (eg, body 
weight, 26.8±0.3 versus 26.4±0.1 g at 10 weeks of 
age; n ≥10 per group). The aorta of Tie2-Nox2KO mice 
showed a significant reduction in Nox2 mRNA levels but 
no changes in the mRNA levels of p22phox, p47phox, p67phox, 
p40phox, SOD1 through SOD3, or catalase (Figure 1C). 
Nox2 mRNA levels were also substantially reduced in cor-
onary microvascular endothelial cells from Tie2-Nox2KO 
mice compared with control (Figure IA in the online-only 
Data Supplement). Nox2 protein levels were significantly 
decreased in Tie2-Nox2KO mouse aorta compared with 
control Flox mice, but there were no differences in p22phox, 
Nox4, or eNOS protein levels (Figure 1D). A Tie2-driven 
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Figure 1. Generation of Tie2-Nox2 knockout (KO) mice.  
A, Targeting strategy for generation of Nox2flox mice (Flox). The endogenous Nox2 locus is shown at the top and the targeting 
vector at the bottom. LoxP sites are represented by blue triangles; FRT sites, by double red triangles. After successful target-
ing, the neomycin (Neo) cassette was excised with the FRT sites. Cre-mediated recombination deletes a 3-kilobase fragment of 
Nox2, including the transcriptional initiation site and the first 2 exons. B, Southern blot analysis of genomic DNA from selected 
ES cell clones screened for 5′-homologous (top) and 3′-homologous (bottom) recombination. The clones 1A3 and 7C11 were 
used for blastocyst injection to generate Nox2flox mice. WT indicates wild-type. C, mRNA levels of Nox2, accessory subunits, 
and antioxidant genes in Tie2-Nox2KO and Flox control aortas. D, Protein levels of Nox2, p22phox, Nox4, and endothelial nitric 
oxide synthase (eNOS) in Tie2-Nox2KO and control aortas. Representative immunoblots are shown above and mean data below. 
#P<0.05 vs Flox.
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deletion of Nox2 was therefore not accompanied by sig-
nificant changes in antioxidant genes, Nox4, or eNOS.
Assessment of ambulatory BP by telemetry revealed 
that Tie2-Nox2KO mice had a significantly lower basal 
systolic BP and mean BP than control Flox mice by 
≈10 mm Hg (Figure 2A and 2B). There were no differ-
ences between groups in heart rate, activity levels, or 
cardiac structure and function assessed by echocar-
diography (Figure 2B and Figure IB in the online-only 
Data Supplement).
Lower Basal BP in Tie2-Nox2KO Is Not 
Accounted for by Altered Renal Function, 
Vascular Remodeling, or Endothelium-Dependent 
Vasodilation
There were no differences between Tie2-Nox2KO and 
control mice in urinary volume, electrolytes, or osmo-
larity in response to a short-term saline challenge (Fig-
ure 3A). To look for vascular remodeling as a basis for 
the lower BP, we quantified intima-media thickness and 
area in aortic sections, but this was also similar between 
groups (Figure 3B). Endothelium-dependent relaxation 
assessed from the vasodilator response to acetylcho-
line in isolated aortic rings was no different between 
Tie2-Nox2KO and control mice (Figure 3C). The vascular 
smooth muscle response to the NO donor sodium nitro-
prusside and the constrictor response to phenylephrine 
were similar in both groups. Acetylcholine-induced vaso-
dilation in mesenteric arteries was also similar between 
groups (Figure 3D).
Vascular and BP Responses of Tie2-Nox2KO Mice 
During AngII Stimulation
After exposure of aortic rings to AngII (0.1 µmol/L for 4 
hours), the phenylephrine-induced vasoconstriction was 
similar in both groups, indicating comparable baselines. 
Acetylcholine-induced vasodilation was significantly 
greater in Tie2-Nox2KO than control mice (Figure 4A, 
Figure 2. Tie2-Nox2 knockout 
(KO) mice have reduced basal 
blood pressure. 
A, Representative telemetric blood 
pressure (BP) traces in Tie2-Nox2KO 
mice and Flox controls. B, Mean data 
for BP, heart rate, and activity level. 
#P<0.05 vs Flox.
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top right). Aortic superoxide levels were similar in Tie2-
Nox2KO and control aorta at baseline but were signifi-
cantly higher in the control group after AngII treatment 
(Figure 4A, top left). In line with this, the superoxide 
scavenger MnTMPyP (10 µmol/L) improved endothelium-
dependent relaxation in the control group but had no sig-
nificant effect in Tie2-Nox2KO (Figure 4A, bottom). We 
also found that short-term NO synthase inhibition with N-
methyl-l-arginine (100 µmol/L) induced greater vasocon-
striction in AngII-treated Tie2-Nox2KO aortic rings than 
AngII-treated control rings (Figure IIA in the online-only 
Data Supplement), suggestive of a greater amount of 
bioactive NO in the former setting. In vivo, the hyperten-
sive response observed in control mice with a 2-week 
infusion of AngII at 1.1 mg·kg−1·d−1 was significantly 
blunted in Tie2-Nox2KO animals, with no difference in the 
heart rate response (Figure 4B). Thus, the blunted hyper-
tensive response to AngII observed in Tie2-Nox2KO mice 
may be attributable to a lower AngII-induced increase in 
endothelial superoxide, a consequent higher level of NO 
bioavailability, and a greater extent of endothelium-de-
pendent vasorelaxation.
Tie2-Nox2KO Mice Have Increased Basal NO 
Bioavailability In Vivo
Although basal ex vivo endothelium-dependent vascular 
function was similar between Tie2-Nox2KO and control 
mice, it is possible that this might be different in vivo 
and that an increase in NO bioavailability caused by a 
reduction in Nox2-derived superoxide may account for 
the lower basal BP in Tie2-Nox2KO. We tested this idea 
by assessing the ambulatory BP response to the NO 
synthase inhibitor L-NAME (100 mg·kg−1·d−1 orally for 2 
days). The hypertensive response to L-NAME was found 
to be significantly greater in Tie2-Nox2KO than control 
mice, such that BP levels were similar in the 2 groups 
after L-NAME treatment (Figure 5A). This finding sug-
gests that in vivo NO bioavailability at baseline may be 
higher in Tie2-Nox2KO than control mice. To assess 
Figure 3. Renal function, vascular remodeling, and in vitro vascular function in Tie2-Nox2 knockout (KO) mice. 
A, Renal function assessed by response to a short-term saline challenge. Changes in urine osmolarity, volume, and sodium and 
potassium concentrations are shown. RM-TW-ANOVA indicates repeated-measures 2-way ANOVA; and N.S., not significant be-
tween groups. B, Representative histological sections of aortas from Tie2-Nox2KO and Flox mice (×40 magnification) and mean 
intima-media area and thickness. C, Concentration-response curves for response of aortic rings to the nitric oxide donor sodium 
nitroprusside (SNP), phenylephrine (PE), and acetylcholine (ACh). D, Concentration-response curves for response of mesenteric 
arteries to ACh.
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whether L-NAME–mediated changes in BP involved the 
vasculature, we used magnetic resonance imaging–
based measurement of resistance artery caliber in vivo 
(by imaging the carotid artery). The carotid artery lumi-
nal area in Tie2-Nox2KO was significantly higher than in 
matched control mice at baseline (0.46±0.03 versus 
0.38±0.02 mm2; n=10 each; P<0.05; Figure 5B and 
5D), consistent with basal vasodilatation. Acetylcho-
Figure 4. Tie2-Nox2 knockout (KO) mice demonstrate blunted in vitro and in vivo responses to  
angiotensin II (AngII). 
A, Top Left, Superoxide levels in Tie2-Nox2KO and Flox aortas at baseline and after AngII stimulation, assessed by high-
performance liquid chromatography of the specific dihydroethidium oxidation product 2-hydroxyethidium (EOH). *P<0.05 vs 
control conditions (2-way-ANOVA). #P<0.05 vs Flox. Top Right, Effect of AngII pretreatment on vasodilation of aortic rings 
to acetylcholine (ACh). Bottom, Effect of MnTMPyP on ACh responses in AngII-treated rings from Flox mice (left) and Tie2-
Nox2KO mice (right). B, Effect of long-term AngII infusion (1.1 mg·kg−1·d−1) on telemetric blood pressure (BP) and heart rate 
in Tie2-Nox2KO and Flox mice. RM-TW-ANOVA indicates repeated-measures 2-way ANOVA. *Significant interaction. #Signifi-
cant difference between genotypes.
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line induced a similar extent of vasodilatation in both 
groups of mice (Figure 5E), consistent with the results 
in ex vivo vessels. After L-NAME treatment, however, 
Tie2-Nox2KO carotid arteries constricted to a great-
er extent than carotid arteries in control mice, such 
that luminal vessel diameters were now similar in both 
groups (Figure 5C and 5F). These results are consistent 
with the notion that a higher in vivo NO bioavailability 
may increase basal resistance vessel caliber in Tie2-
Nox2KO mice.
Figure 5. Tie2-Nox2 knockout (KO) mice have increased basal nitric oxide (NO) bioavailability in vivo. 
A, Blood pressure (BP) response to Nω-nitro-l-arginine methyl ester (L-NAME) in Tie2-Nox2KO and Flox mice, assessed by telem-
etry. *Significant interaction as tested by repeated-measures 2-way ANOVA (RM-TW-ANOVA). #Significant difference between 
genotypes. B and C, Representative magnetic resonance images of the carotid artery in Tie2-Nox2KO and Flox mice at baseline 
(B) and after L-NAME treatment (C). Scale bar, 1 mm. D through F, Mean data for diastolic area of the carotid artery at base-
line (D), after acetylcholine (ACh) treatment (E), and after L-NAME treatment (F). *P<0.05 vs control conditions (TW-ANOVA). 
#P<0.05 vs Flox. 
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Contrasting Roles of Endothelial Versus Myeloid 
Immune Cell Nox2 in BP Regulation
The data presented so far suggest that the lower basal 
BP in Tie2-Nox2KO animals involves an NO-dependent 
mechanism but cannot be accounted for by altered en-
dothelial function. Because Tie2 is expressed not only 
in endothelial cells but also in myelomonocytic cells,31 
we considered the possibility that the results observed 
in Tie2-Nox2KO mice might be related to Nox2 deletion 
in myeloid cells. Indeed, Tie2-Nox2KO mice showed 
clear evidence of Cre-mediated recombination in bone 
marrow–derived cells (Figure 6A). Furthermore, Tie2-
Nox2KO bone marrow cells and circulating mononuclear 
cells displayed functionally deficient Nox2-derived ROS 
production (Figure 6B).
To investigate whether Nox2 in myeloid cells con-
tributes to the effects on basal BP, we next generated 
a myeloid-specific Nox2KO model using a LysM-Cre 
mouse line that targets myelomonocytic cells18 (Fig-
ure IIB in the online-only Data Supplement). LysM-Cre-
Nox2KO mice showed no obvious gross phenotype and 
had comparable amounts of myeloid inflammatory cells 
in the vessel wall (Table I in the online-only Data Supple-
ment). However, ambulatory BP monitoring by telemetry 
revealed a significant reduction in basal systolic BP com-
pared to control Flox mice, similar to that observed in 
Tie2-Nox2KO animals, with no alteration in heart rate 
(Figure 6C). To assess whether this reduction in basal 
BP was related to increased in vivo NO bioavailability, 
LysM-Cre-Nox2KO mice and controls were treated with 
L-NAME. Indeed, we found that after L-NAME treatment, 
which had hypertensive effects in both groups of mice, 
the systolic BP was similar in LysM-Cre-Nox2KO and con-
trols (Figure 6D). To more directly assess basal vascular 
NO levels, we performed EPR with NO-Fe(DETC)2 spin 
trapping (Figure 6E). Aortic NO levels were significantly 
higher in LysM-Cre-Nox2KO mice than controls, consis-
tent with the higher NO bioavailability in vivo (Figure 6D). 
It is interesting to note that although basal aortic NO 
levels were increased in LysM-Cre-Nox2KO, iNOS-de-
rived NO formation as assessed after lipopolysaccha-
ride stimulation was lower than in controls (Figure IIIA in 
the online-only Data Supplement). We also studied the 
response of LysM-Cre-Nox2KO mice to AngII infusion. In 
contrast to the differences in basal BP, the hypertensive 
response to AngII was similar in LysM-Cre-Nox2KO and 
control mice (Figure IIIB in the online-only Data Supple-
ment), indicating that myeloid cell Nox2 does not appear 
to modulate AngII-dependent hypertension.
To elucidate the specific role of Nox2 in the endotheli-
um, we then generated an inducible endothelial Nox2KO 
model using a Cdh5-CreERT2 driver line.19 In this model, 
endothelium-specific Nox2 deletion was achieved in adult 
mice by tamoxifen treatment (Figure IIC in the online-only 
Data Supplement). Tamoxifen treatment had no effect on 
cardiac function (Figure IID in the online-only Data Supple-
ment). In contrast to LysM-Cre-Nox2KO mice, Cdh5-Cre-
ERT2-Nox2KO animals showed no difference in basal BP 
compared with matched controls as assessed by ambu-
latory telemetry (Figure 7A). The hypertensive response 
to L-NAME was also similar in both groups (Figure 7B), 
suggesting a comparable NO bioavailability under basal 
conditions in this model. The quantification of basal aor-
tic NO levels by EPR confirmed that they were similar 
between groups (Figure 7C). AngII-induced hypertension, 
however, was significantly attenuated in Cdh5-CreERT2-
Nox2KO mice (Figure IIIC in the online-only Data Supple-
ment), pointing to endothelial Nox2 as a crucial player in 
AngII-mediated hypertension.
DISCUSSION
This study provides significant new insights into the role 
of Nox2 in the regulation of BP. With the use of sev-
eral novel cell-specific Nox2KO models, we were able 
to dissect out and distinguish between the effects of 
myelomonocytic cell Nox2 on basal BP and those of 
endothelial cell Nox2 on AngII-induced hypertension. We 
accordingly identified cell-specific and context-specific 
roles for Nox2 in BP regulation that indicate that the 
roles of ROS are highly complex not only among differ-
ent ROS sources but also for the same source in differ-
ent cell types.
An important and unexpected initial finding was that 
Tie2-Nox2KO mice, which we generated as a model of 
endothelium-specific Nox2 deletion, exhibited significant-
ly lower basal BP compared with matched controls. Al-
though some previous studies have reported a lower BP 
in global Nox2KO mice,32,33 it was not immediately obvi-
ous why the deletion of endothelial Nox2 should affect 
basal BP. For example, previous work from our group21 
and others34 showed that endothelium-specific overex-
pression of Nox2 had no effect on basal BP. Compensa-
tory changes in other enzymes such as the antioxidants 
SOD1 through SOD3 and catalase, eNOS, or Nox4 could 
conceivably be involved (and Nox4 was previously linked 
to lower BP26), but we found no differences in the lev-
els of these enzymes between Tie2-Nox2KO and control 
mice. The investigation of ex vivo endothelium-dependent 
function in Tie2-Nox2KO mouse aorta and mesenteric ar-
tery did not reveal any enhancement of relaxation, in line 
with the finding that basal vascular O2
− production was 
unaltered. We also found no changes in cardiac or renal 
function and no evidence of structural vascular remodel-
ing to explain the lower BP. Nevertheless, the lower BP 
in Tie2-Nox2KO mice was related to an enhanced in vivo 
NO bioavailability as indicated by the normalization of the 
BP difference on treatment with L-NAME. Furthermore, 
in vivo assessment of resistance vessel function by 
magnetic resonance imaging revealed that Tie2-Nox2KO 
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Figure 6. LysM-Cre-Nox2 knockout (KO) mice have reduced basal blood pressure (BP) and increased vascular 
nitric oxide (NO) bioavailability. 
A, Cre-mediated recombination in bone marrow–derived cells from Tie2-Nox2KO mice. WT indicates wild-type. B, Functionally 
deficient reactive oxygen species production in phorbol ester (PMA)–stimulated bone marrow cells and circulating (Continued )
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mice had a pronounced vasodilatation under basal con-
ditions that could be reversed by L-NAME treatment but 
showed no evidence of altered endothelium-dependent 
relaxation. Taken together, these findings led us to con-
sider the possibility that nonendothelial Nox2-containing 
cells may be involved in the effect on basal BP. In this 
regard, it is known that Tie2 is expressed not only in 
endothelial cells but also in certain hematopoietic cells, 
notably monocytic cells.31,35 Indeed, we confirmed that 
the Tie2-Cre approach not only targeted endothelial cells 
but also induced functional Nox2 deletion in myelomono-
cytic cells.
Figure 7. Cdh5-CreERT2-Nox2 knockout (KO) mice have unaltered basal blood pressure (BP). 
A, Telemetric BP and heart rate at baseline. B, BP responses to Nω-nitro-l-arginine methyl ester (L-NAME) in Cdh5-CreERT2-
Nox2KO and Flox mice. L-NAME increased BP in both groups, but there was no significant difference between groups by 
repeated-measures 2-way ANOVA (RM-TW-ANOVA). C, Comparable aortic nitric oxide (NO) levels in Cdh5-CreERT2-Nox2KO and 
controls under basal conditions, as assessed by electron paramagnetic resonance (EPR). Representative EPR spectra are shown 
on the right.
Figure 6 Continued. mononuclear cells from Tie2-Nox2KO mice, assessed by flow cytometry in cells loaded with dihydro-
ethidium. C, Reduced basal BP (telemetry) in LysM-Cre-Nox2KO mice. #P<0.05 vs Flox. D, In vivo response to Nω-nitro-l-arginine 
methyl ester (L-NAME) in LysM-Cre-Nox2KO mice and controls. #Significance vs Flox as tested by repeated-measures 2-way 
ANOVA (RM-TW-ANOVA). E. Increased aortic NO levels in LysM-Cre-Nox2KO under basal conditions, as assessed by electron 
paramagnetic resonance (EPR). Representative EPR spectra are shown on the right. #P<0.05 vs Flox.
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The generation of novel LysM-Cre-Nox2KO and Cdh5-
CreERT2-Nox2KO mice then allowed us to establish that 
the reduction in basal BP was in fact related to deletion 
of Nox2 from myelomonocytic cells rather than endothe-
lial cells, with an associated increase in in vivo NO bio-
availability. Using EPR with NO-Fe(DETC)2 spin trapping, 
we found that the aortas of LysM-Cre-Nox2KO mice had 
increased NO levels, pointing to the vasculature as the 
likely site of action of myelomonocytic cells with disrupt-
ed Nox2. Conversely, Cdh5-CreERT2-Nox2KO aortas 
had unaltered vascular NO levels under basal conditions. 
It should be noted that the magnitude of difference in 
NO levels observed in aorta cannot necessarily be ex-
trapolated to the resistance vasculature, which is the 
more important vascular site for BP regulation. The ef-
fect of myelomonocytic cells in the vasculature is most 
likely to reflect the inactivation of endothelium-derived 
NO by myeloid Nox2-derived superoxide, before the NO 
can affect vascular smooth muscle cell relaxation. When 
myelomonocytic Nox2 is disrupted, the levels of bioac-
tive NO would accordingly rise. Consistent with this idea, 
we could demonstrate the presence of myelomonocytic 
cells in the aortas of both LysM-Cre-Nox2KO and control 
mice but with no difference in the number of cells be-
tween groups. Myelomonocytic cells could in principle 
produce NO from iNOS, but we found that iNOS-derived 
NO (after lipopolysaccharide stimulation) was decreased 
in LysM-Cre-Nox2KO mice, consistent with previous re-
ports that Nox-dependent signaling can increase iNOS 
expression,36 making it unlikely that myeloid cell iNOS 
plays a role in the observed changes in basal BP. The 
reason the deletion of only myelomonocytic Nox2 but 
not endothelial Nox2 affects basal BP is most likely that 
the abundance of Nox2 is much lower in endothelial 
cells than myeloid cells.37 We did note, however, that 
the reduction in basal BP was slightly higher in the Tie2-
Nox2KO mice (in which both myeloid and endothelial cell 
Nox2 is deleted) than in LysM-Cre-Nox2KO. This could in-
dicate that the effects of myelomonocytic Nox2KO may 
be enhanced by the concomitant knockout of endothelial 
cell Nox2. The present results are, to the best of our 
knowledge, the first indication that myelomonocytic cell 
Nox2 modulates basal BP.
AngII is a potent activator of both Nox1 and Nox2, 
and an impact of Nox enzymes on AngII-induced hyper-
tension has been documented in many previous stud-
ies, as discussed earlier. However, the specific roles 
of different Nox isoforms and different cell types have 
remained unclear. Quite strong evidence supports a role 
for vascular smooth muscle Nox1 in AngII-induced hyper-
tension, involving changes in vascular remodeling.10,11 
The cell-specific role of Nox2 is unclear, but this a per-
tinent question because Nox2 is expressed in endothe-
lial cells, cardiomyocytes, fibroblasts, certain vascular 
smooth muscle cells, and inflammatory/immune cells.6 
Nox2 is involved in the genesis of endothelial dysfunc-
tion in diverse models,6,7 and previous studies from our 
laboratory21 and others32 found that endothelium-targeted 
overexpression of Nox2 enhanced AngII-induced hyper-
tension. However, the role of endogenous endothelial 
Nox2 was not established in those studies. The present 
results in Cdh5-CreERT-Nox2KO mice and Tie2-Nox2KO 
mice clearly establish that endogenous endothelial Nox2 
augments AngII-induced hypertension, at least in the 
relatively short term (2 weeks). It is interesting to note 
that AngII-induced hypertension was comparable in LysM-
Cre-Nox2KO and respective control mice, indicating that 
constitutive deficiency of Nox2 in myelomonocytic cells 
is apparently not important in this setting. On the other 
hand, previous data suggest that T-cell Nox215 and Nox2 
in the subfornical organ,12,13 and possibly Nox2 in renal 
afferent arterioles,14 also modulate AngII-induced hyper-
tension. Furthermore, it was also shown that mice can be 
protected from arterial hypertension when LysM-positive 
cells are depleted before the AngII infusion is begun and 
that BP can be restored by adoptive transfer of Nox2-
competent monocytes into these mice.16 Taken together, 
these data indicate complex roles during AngII-induced 
hypertension for Nox2 in multiple cell types, some that 
involve altered NO bioavailability and others that may in-
volve Nox2-dependent redox signaling events. The endo-
thelium-dependent effects of Nox2 defined in the present 
study appear to involve an increased inactivation of NO 
by ROS, which affects endothelium-dependent relaxation, 
as suggested by our ex vivo studies, but could potentially 
also affect other NO-dependent functions.
The major new finding of this study is the potential 
for myelomonocytic cells to affect basal BP in a revers-
ible manner. Although the absolute change in basal BP is 
modest, its magnitude is similar to that of changes that 
would be considered clinically or prognostically signifi-
cant, for example, in hypertension. From a pathophysio-
logical perspective, it is interesting to speculate whether 
the effects of these cells on BP might be enhanced in 
disease settings where monocytes are activated, for ex-
ample, inflammatory conditions. In this regard, patients 
with chronic granulomatous disease, who have function-
ally deficient Nox2 activity, might be of particular interest. 
More broadly, the present results suggest the potential 
for different disease conditions to alter BP through Nox2-
dependent effects in distinct cell types, that is, myeloid 
cells or endothelial cells. In terms of renin-angiotensin-al-
dosterone system–dependent hypertension, Nox2 inhibi-
tion would be anticipated to be beneficial, and combined 
Nox1/Nox2 inhibitors could be of particular value given 
the effects of both isoforms to increase BP. 
CONCLUSIONS
This study identifies distinct effects of myeloid cell Nox2 
and endothelial cell Nox2 on basal and AngII-dependent 
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BP, respectively, and suggests that Nox2 may be a mas-
ter regulator of BP.
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Supplementary Table 1.  Aortic myelo-monotic and lymphatic cells in Flox control and 
LysM-Cre-Nox2KO mice.  
Flox control LysM-Cre 
Nox2KO 
Cell type Number of 
cells / 10 mg 
aortic tissue 
n Number of 
cells 10 / mg 
aortic tissue 
n P 
CD45+CD11b+ Ly6G- 
(Monocytes) 
100 ± 60 4 120 ± 20 5 N.S.
CD45+CD11b+ F4/80+ 
(Macrophages) 
3.5 ± 2.2 4 8.1 ± 1.3 5 N.S.
CD45+CD11b+ Ly6G+ 
(Neutrophils) 
540 ± 230 5 580 ± 80 5 N.S.
CD45+TCRβ+ 
(T-Lymphocytes) 
790 ± 340 5 810 ± 110 5 N.S.
CD45+CD19+ 
(B-Lymphocytes) 
640 ± 310 5 640 ± 90 5 N.S.
Data are mean±SEM. 
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Supplementary Figure 1. Coronary microvascular endothelial cell mRNA levels and 
cardiac echocardiography. 
A. mRNA levels of Nox2 and Nox4 in coronary microvascular endothelial cells (CMEC). #, 
P<0.05 vs. Flox. B. Echocardiographic parameters of cardiac structure and function, and left 
ventricle/body weight ratio (LV/BW). IVSD, interventricular septal diameter. 
 
 
Supplementary Figure 2.  Generation of LysM-Cre-Nox2KO and Cdh5-CreERT2-
Nox2KO mice. 
A. Magnitude of L-NMMA-induced constriction in AngII-treated aortic rings from Tie2-
Nox2KO mice and Flox controls. *, P<0.05 vs. Flox. B. Cre-mediated recombination in Cre+ 
bone marrow cells from LysM-Cre-Nox2KO mice. C. Cre-mediated recombination in Cre+ 
lung tissue from Cdh5-CreERT2-Nox2KO mice. D. Left ventricular ejection fraction in Cdh5-
CreERT2-Nox2KO cf. Flox mice following Tamoxifen treatment.     
 
 
Supplementary Figure 3. Hypertensive response to AngII in LysM-Cre-Nox2KO and 
Cdh5-CreERT2-Nox2KO mice. 
A. Reduced aortic iNOS-derived NO formation in LysM-Cre-Nox2KO after LPS stimulation. #, 
P<0.05 vs. Flox. Representative EPR spectra shown to the right. B. In vivo response to AngII 
infusion in LysM-Cre-Nox2KO mice and Flox control. C. In vivo response to AngII infusion in 
Cdh5-CreERT2-Nox2KO mice and respective control. RM-TW-ANOVA = repeated measures 
two-way ANOVA. #, P<0.05 vs. Flox control.     
 
 
